ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod...
August 28, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...
$478 million in second quarter global net product sales First CIDP patients treated with VYVGART® Hytrulo...
July 18, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...
First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent...
ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse...
VYVGART® Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory...
R&D Day presentations to include recent Phase 2 datasets in Sjogren’s disease (efgartigimod) and...
June 4, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...
$398 million in first quarter global net product sales FDA review ongoing for CIDP sBLA with PDUFA target...
May 7, 2024 – 5:30pm ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global...
May 7, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...
May 2, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...
ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years...
RHO study supports proof-of-concept in primary Sjogren’s disease Decision informed by favorable...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.